Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

25 Aug 2025 1:35 AM | Anonymous member (Administrator)

Kohei Shitara; Sylvie Lorenzen; Jin Li; Yuxian Bai; Manuel González Fernández; Mynor Aguilar; Hirokazu Shoji; Felipe Reyes-Cosmelli; Yovany Rodriguez Peña; Luis Corrales; Lucjan Wyrwicz; Daniel Acosta Eyzaguirre; Yueyin Pan; Min-Hee Ryu; Deirdre J. Cohen; Zev A. Wainberg; Geoffrey Ku; Josep Tabernero; Eric Van Cutsem; Shu-Kui Qin; Do-Youn Oh; Jianming Xu; Li Wen Liang; Sonal Bordia; Pooja Bhagia; Sun Young Rha

Read Abstract: Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software